To combat COVID-19, parts of Asia continue to implement a zero-COVID strategy. The strategy means strict lockdowns, travel disruptions and more. And the impact to site-centric clinical trials is significant.
Many organizations conducting clinical trials in Asia are moving to a patient-centric clinical trial model. To offer direct-to-patient and direct-from-patient shipping in this model means a shift in how temperature control is managed, including less use of temperature-controlled vehicles and more use of easy-to-use temperature-controlled packaging.
To learn more about the clinical trials changes happening in Asia, check out the most recent issue of the Journal for Clinical Studies.